RP115
Alzheimer's Disease
Key Facts
About Rio Pharmaceuticals
Rio Pharmaceuticals is a clinical-stage diagnostics company pioneering PET imaging tracers for neurological conditions like Alzheimer's disease and ALS. Its core technology focuses on imaging the EAAT2 transporter, a key protein involved in glutamate regulation and neuroinflammation, providing a potential early biomarker for disease pathology. The company is advancing its lead candidate, RP115, through multiple clinical trials with support from NIH and the Department of Defense, and is led by a team with deep expertise in neurology, PET imaging, and CNS drug development. As a private, pre-revenue entity, Rio aims to address a significant unmet need in neurological disease diagnostics.
View full company profileAbout Rio Pharmaceuticals
Rio Pharmaceuticals is a clinical-stage diagnostics company pioneering PET imaging tracers for neurological conditions like Alzheimer's disease and ALS. Its core technology focuses on imaging the EAAT2 transporter, a key protein involved in glutamate regulation and neuroinflammation, providing a potential early biomarker for disease pathology. The company is advancing its lead candidate, RP115, through multiple clinical trials with support from NIH and the Department of Defense, and is led by a team with deep expertise in neurology, PET imaging, and CNS drug development. As a private, pre-revenue entity, Rio aims to address a significant unmet need in neurological disease diagnostics.
View full company profileOther Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |